CClinicalTrials.gg
CompletedNCT04468802Updated Jul 14, 2020

Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?

An observational study in Covid19, Measles Vaccine and Mortality, sponsored by Kanuni Sultan Suleyman Training and Research Hospital. Completed at 1 site in Turkey. Per ClinicalTrials.gov, last updated 2020-07-14.

Sponsored by Kanuni Sultan Suleyman Training and Research Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
32
Sex
All
01

Study summary

Mortality rates caused by SARS CoV-2 differ between countries and this difference might be explained by several reasons. Childhood vaccination rate is thought to be one of them. Therefore present study aimed to examine the possible relationship between DTaP (diphtheria, tetanus, pertussis) and measles vaccination rates of Organization for Economic Co-operation and Development (OECD) countries and case fatality rate (CFR) caused by SARS CoV-2.

Read the detailed description

The mortality rates caused by SARS CoV-2 differ between countries and this difference might be explained by several reasons. Childhood vaccination rate is thought to be one of them. Therefore present study aimed to examine the possible relationship between DTaP (diphtheria, tetanus, pertussis) and measles vaccination rates of Organization for Economic Co-operation and Development (OECD) countries and case fatality rate (CFR) caused by SARS CoV-2.A total of 32 OECD countries, of northern hemisphere, have been included in this study. Statistical analysis performed according to the CFR data of these countries based on SARS CoV-2. The CFR data calculated according to the total mortality count of a specific country for the 3-month period down from the date when first SARS CoV-2 case was observed.

02

Conditions studied

  • Covid19
  • Measles Vaccine
  • Mortality

Browse trials for

03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Children vaccinated in OECD countries in northern hemisphere

Inclusion criteria

  • Children vaccinated in OECD countries in northern hemisphere

Exclusion criteria

Exclusion Criteria:

  • Non vaccinated children
  • Southern hemisphere countries
  • non-OECD countries
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
32 participants (actual)
Patient registry
No

Interventions

  • OtherCase fatality rate

    Mortality rate caused by SARS CoV-2

05

What researchers measure

Primary outcomes

  1. Case Fatality Rate

    Mortality rate caused by SARS CoV-2

    Time frame: 4 months

06

Study locations

1 site
  • Istanbul Kanuni Sultan Suleyman Training and Research Hospital
    Istanbul, Kucukcekmece 34303, Turkey
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04468802
Lead sponsor
Kanuni Sultan Suleyman Training and Research Hospital
Responsible party
Ramazan Guven (Professor, Kanuni Sultan Suleyman Training and Research Hospital) — Principal investigator
First posted
Jul 13, 2020
Start date
Feb 1, 2020
Primary completion
Jun 30, 2020
Completion
Jul 1, 2020
Last update
Jul 14, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion